Improved therapeutic consistency and efficacy of mesenchymal stem cells expanded with chemically defined medium for systemic lupus erythematosus
Authors:
- 5 February 2020
- journal article
- editorial
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 17 (10) , 1104-1106
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Additive Therapeutic Effects of Mesenchymal Stem Cells and IL-37 for Systemic Lupus ErythematosusJournal of the American Society of Nephrology, 2019
- Understanding the Immunological Mechanisms of Mesenchymal Stem Cells in Allogeneic Transplantation: From the Aspect of Major Histocompatibility Complex Class IStem Cells and Development, 2019
- Manufacturing of human Wharton's jelly stem cells for clinical use: selection of serum is importantCytotherapy, 2019
- Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipientsNature Biotechnology, 2019
- Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseasesNature Reviews Nephrology, 2018
- Global phenotypic characterisation of human platelet lysate expanded MSCs by high-throughput flow cytometryScientific Reports, 2018
- Standardization of Good Manufacturing Practice–compliant production of bone marrow–derived human mesenchymal stromal cells for immunotherapeutic applicationsCytotherapy, 2015
- Mesenchymal stem cells: immune evasive, not immune privilegedNature Biotechnology, 2014